Table 4

ORs for breast cancer by quartiles of serum protein measurements for postmenopausal women

QuartileQuartile 4 95% CIP for trend
1234
IGF-I (ng/ml)
Median153203250330
Range95–173176–227230–284288–450
Cases/controls18/1315/1513/1614/16
OR, crude1.00.720.590.630.23–1.760.37
OR, adjusteda1.01.040.560.770.23–2.560.067
OR, adjustedb1.01.270.381.220.21–6.780.74
IGFBP-1 (ng/ml)
Median9.430.849.276.4
Range0.8–20.921.3–35.736.6–56.258.3–158.2
Cases/controls17/1315/1511/1917/13
OR, crude1.00.760.441.00.36–2.800.85
OR, adjustedc1.01.070.541.960.35–10.90.75
IGFBP-2 (ng/ml)
Median245402539810
Range18–324339–473477–631651–1394
Cases/controls17/1320/1015/168/21
OR, crude1.01.530.720.290.09–0.920.007
OR, adjustedd1.03.231.360.110.02–0.660.002
IGFBP-3 (ng/ml)
Median1660207024103040
Range980–18701880–22302240–26202630–4250
Cases/controls16/1417/1317/1310/20
OR, crude1.01.141.140.440.15–1.280.10
OR, adjustedc1.01.220.970.320.07–1.410.09
  • a Adjusted for insulin, glucose, and BMI.

  • b Adjusted for insulin, glucose, BMI, and IGFBP-3.

  • c Adjusted for insulin, glucose, BMI, and IGF-I.

  • d Adjusted for insulin, glucose, and IGF-I.